Broccoli Sprout Extract in Preventing Lung Cancer in Smokers
This study is currently recruiting patients.
Verified by National Cancer Institute (NCI) April 2006
| Sponsors and Collaborators: |
Sidney Kimmel Comprehensive Cancer Center
|
| Information provided by: |
National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: |
NCT00255775 | |
Purpose
RATIONALE: Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of broccoli sprout extract may prevent lung cancer.
PURPOSE: This clinical trial is studying how well broccoli sprout extract works in preventing lung cancer in smokers.
| Condition |
Intervention |
Non-Small Cell Lung Cancer Small Cell Lung Cancer
|
Drug: broccoli sprout extract Procedure: biologically based therapies Procedure: cancer prevention intervention Procedure: chemoprevention of cancer Procedure: complementary and alternative therapy Procedure: dietary intervention Procedure: herbal medicine / botanical therapy Procedure: nutritional supplementation
|
MedlinePlus related topics: Lung Cancer
Study Type: Interventional
Study Design: Prevention
Official Title: Chemoprevention Study of Broccoli Sprout Extract in Smokers
Further study details as provided by National Cancer Institute (NCI):
OBJECTIVES:
Primary
- Evaluate the effect of broccoli sprout extract on levels of DNA adducts in participants who smoke.
- Determine the effectiveness of broccoli sprout extract in reducing tobacco-carcinogen induced DNA adducts in these participants.
Secondary
- Determine the effects of broccoli sprout extract on markers of the Nrf2 pathway in these participants.
- Determine the effectiveness of broccoli sprout extract, in increasing the activity of the Nrf2 pathway, in these participants.
- Evaluate the feasibility of using lymphocytes and buccal cells to monitor DNA adducts and changes in the Nrf2 pathway in these participants.
OUTLINE: Participants are stratified according to GST genotypic polymorphism (M1 vs T1).
Participants receive oral broccoli sprout extract daily for 3 weeks. Participants keep a daily diary of their eating and smoking habits for 3 weeks before, during, and for 3 weeks after study treatment. They must continue to smoke during the study, but are encouraged to quit after completing the study treatment.
PROJECTED ACCRUAL: A total of 70 participants will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Current smoker with ≥ 30 pack-year history of smoking
PATIENT CHARACTERISTICS:
Performance status
Life expectancy
Hematopoietic
- WBC > 4,000/mm^3
- Platelet count > 100,000/mm^3
Hepatic
Renal
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile participants must use effective contraception
- No other medical condition that would preclude study treatment or compliance
- No gastrointestinal condition that would affect absorption, preclude taking oral medication, or necessitate IV alimentation
PRIOR CONCURRENT THERAPY:
Surgery
- No prior surgery affecting absorption
Other
- More than 6 weeks since prior vitamins, herbal supplements, non-steroidal anti-inflammatory drugs, or antibiotics
- No concurrent dietary intake of cruciferous vegetables
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00255775
Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-2410, United States; Recruiting
Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce 410-955-8804
jhcccro@jhmi.edu
Study chairs or principal investigators
Julie Brahmer, MD, Study Chair, Sidney Kimmel Comprehensive Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers: CDR0000450158; JHOC-J0427; JHOC-04051801
Last Updated: June 7, 2006
Record first received: November 18, 2005
ClinicalTrials.gov Identifier:
NCT00255775Health Authority: United States: Federal Government
Related Articles